Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the P-32-postlabeling technique

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11310%2F12%3A10126293" target="_blank" >RIV/00216208:11310/12:10126293 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/12:8184 RIV/00064203:_____/12:8184

Výsledek na webu

<a href="http://dx.doi.org/10.5507/bp.2012.043" target="_blank" >http://dx.doi.org/10.5507/bp.2012.043</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2012.043" target="_blank" >10.5507/bp.2012.043</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the P-32-postlabeling technique

Popis výsledku v původním jazyce

Ellipticine and doxorubicin are antineoplastic agents, whose action is based mainly on DNA damage such as intercalation, inhibition of topoisomerase II and formation of covalent DNA adducts. The key target to resolve which of these mechanisms are responsible for ellipticine and doxorubicin anticancer effects is the development of suitable methods for identifying their individual DNA-damaging effects. Here, the P-32-postlabeling method was tested to detect covalent DNA adducts formed by ellipticine and doxorubicin. Results. Two covalent ellipticine-derived DNA adducts, which are associated with cytotoxicity of ellipticine to human UKF-NB-3 and UKF-NB-4 neuroblastoma cell lines, were detected by the P-32-postlabeling method. These adducts are identical to those formed by the ellipticine metabolites, 13-hydroxy- and 12-hydroxyellipticine. In contrast, no covalent adducts formed by doxorubicin in DNA of these neuroblastoma cells and in DNA incubated with this drug and formaldehyde in vitro

Název v anglickém jazyce

Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the P-32-postlabeling technique

Popis výsledku anglicky

Ellipticine and doxorubicin are antineoplastic agents, whose action is based mainly on DNA damage such as intercalation, inhibition of topoisomerase II and formation of covalent DNA adducts. The key target to resolve which of these mechanisms are responsible for ellipticine and doxorubicin anticancer effects is the development of suitable methods for identifying their individual DNA-damaging effects. Here, the P-32-postlabeling method was tested to detect covalent DNA adducts formed by ellipticine and doxorubicin. Results. Two covalent ellipticine-derived DNA adducts, which are associated with cytotoxicity of ellipticine to human UKF-NB-3 and UKF-NB-4 neuroblastoma cell lines, were detected by the P-32-postlabeling method. These adducts are identical to those formed by the ellipticine metabolites, 13-hydroxy- and 12-hydroxyellipticine. In contrast, no covalent adducts formed by doxorubicin in DNA of these neuroblastoma cells and in DNA incubated with this drug and formaldehyde in vitro

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

CE - Biochemie

OECD FORD obor

—

Projekt

<a href="/cs/project/GAP301%2F10%2F0356" target="_blank" >GAP301/10/0356: Studie participace specifických mechanismů poškození DNA na cytoxicitě cytostatik vůči lidským chemosensitivním a chemorestentním neuroblastomům</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, CzechoSK

ISSN

1213-8118

e-ISSN

—

Svazek periodika

156

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

7

Strana od-do

115-121

Kód UT WoS článku

000306401700005

EID výsledku v databázi Scopus

—